FIELD: chemistry.
SUBSTANCE: present invention relates to immunology. Disclosed is an anti-α5β1 antibody, which is described through amino acid sequences of six hypervariable regions and an antigen-binding moiety thereof. Described are conjugates of the disclosed antibodies with a medicinal agent or a label, a pharmaceutical composition, use of the disclosed antibodies to prepare a medicinal agent, methods and an industrial product for inhibiting angiogenesis and/or vascular permeability in a subject, and for treating cancer, an ophthalmic disease and an autoimmune disease in a subject. The invention describes an isolated nucleic acid, an expression vector, a cell and a method of producing an antibody or an antigen-binding moiety thereof, as well as a method of detecting α5β1 protein in a sample.
EFFECT: present invention can find further use in therapy and diagnosis of α5β1-mediated diseases.
52 cl, 11 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY WITH USING ALPHA5BETA1 ANTAGONISTS | 2007 |
|
RU2465282C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
| ANTI-ANGIOGENESIS THERAPY FOR TREATING PREVIOUSLY TREATED BREAST CANCER | 2010 |
|
RU2576027C2 |
| CHIMERIC AND HUMANISED INTEGRIN α5β1 ANTIBODIES MODULATING ANGIOGENESIS | 2003 |
|
RU2346701C2 |
| ANTI-BV8 ANTIBODIES AND USING THEM | 2010 |
|
RU2559542C2 |
| ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) | 2008 |
|
RU2514148C2 |
| ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) | 2013 |
|
RU2639506C2 |
| ANGIOPOIETIC ANGIOPOIETIN-LIKE PROTEIN 4 INHIBITORS, IN COMBINATIONS AND APPLICATION | 2005 |
|
RU2392966C2 |
| ANGIOGENESIS INHIBITION | 2008 |
|
RU2471498C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
